3,819
Participants
Start Date
November 30, 2013
Primary Completion Date
June 30, 2017
Study Completion Date
June 30, 2017
Integrated prenatal screening for Down's syndrome
Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.
Serum QUAD Assay for aneuploidy screening
Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy
Semiconductor MPSS NIPT assay using ccfDNA in maternal blood
Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.
Optical-based MPSS NIPT assay using ccfDNA in maternal blood
Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.
Harmony™ Test (Ariosa Diagnostics)
Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)
Foothills Medical Centre, Calgary
Children's & Women's Health Centre, Vancouver
The Ottawa Hospital, Ottawa
CHU Ste-Justine, Montreal
CHU de Québec, Québec
Laval University
OTHER
Genome Canada
OTHER
Genome Quebec
OTHER
Genome British Columbia
INDUSTRY
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
CHU de Quebec-Universite Laval
OTHER